

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

- (1) ESTABLISHMENT OF STRATEGIC COMMITTEE;**
- (2) ESTABLISHMENT OF COMMERCIALIZATION COMMITTEE;**
- (3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;**
- (4) APPOINTMENT OF MEMBERS OF THE STRATEGIC COMMITTEE AND COMMERCIALIZATION COMMITTEE; AND**
- (5) CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE**

ESTABLISHMENT OF STRATEGIC COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort NeuroScientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, with effect from December 29, 2025, the Board resolved to establish the strategic committee of the Board (the “**Strategic Committee**”). The establishment of the Strategic Committee aims to conduct researches and submit proposals regarding the long-term development strategies and major development decisions of the Company. Driven by innovation, the Company continuously improves its comprehensive stroke treatment solutions, actively explores new frontiers in brain science, and recently established the Chaos Brain-Computer Research Institute. Simultaneously, the Company actively promotes its global business layout and continuously enhances its international brand influence. The establishment of the Strategic Committee is based on the Company’s long-term development needs, aligning with policy support and industry opportunities in the field of brain science, providing systematic guidance for the planning and implementation of the Company’s medium- and long-term strategies, and promoting the implementation and upgrading of these strategies.

ESTABLISHMENT OF COMMERCIALIZATION COMMITTEE

The Board hereby announces that, with effect from December 29, 2025, the Board resolved to establish the commercialization committee of the Board (the “**Commercialization Committee**”). The establishment of the Commercialization Committee aims to further optimize the planning and implementation of the Company’s commercialization system, and to fully leverage on the guidance of the Commercialization Committee, so as to enhance the competitiveness edges of the Company’s products in the market during commercialization.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

This section is made by the Company pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board is pleased to announce that Mr. Liu Thomas A. (劉安) (“**Mr. Liu**”) has been appointed as an independent non-executive Director to the Board with effect from December 29, 2025.

Mr. Liu, born in 1964, was appointed as the independent non-executive Director on December 29, 2025.

Mr. Liu is a seasoned executive with over 30 years of senior leadership experience in supply chain logistics, manufacturing, industrial automation, risk management, and operations across Asia Pacific, North America, and Europe. He currently serves as a senior advisor of China Harbour Engineering Company Limited and Investment Committee member of Hong Kong Science and Technology Parks Corporation. From August 2022 to August 2023, Mr. Liu served as an independent director of GigaCloud Technology Inc. (a company listed on NASDAQ, stock symbol: GCT). From September 2020 to December 2023, Mr. Liu served as the President of Greater China of Prologis Inc., overseeing operations, business development, capital deployment, venture capital investment, and mergers and acquisitions. Prior to these roles, from September 2014 to March 2020, Mr. Liu served as Head of Wanda Capital, overseeing capital deployment, strategic acquisition, fundraising and risk management for Dalian Wanda Group, a cross-industry multinational conglomerate. Furthermore, Mr. Liu’s earlier roles include managing director at Blue Ridge Capital from August 2009 to September 2014, where he led operational value-add initiatives and fundraising, and a managing director at Honeywell Greater China from June 2006 to August 2009, where he propelled the company’s substantial revenue growth. Mr. Liu also held leadership positions at Lear Corporation and Johnson Controls, driving significant growth in automotive and manufacturing sectors.

Mr. Liu received his bachelor's degree in manufacturing systems engineering from GMI Engineering & Management Institute (currently known as Kettering University) in September 1989, his master's degree in systems design engineering from University of Waterloo in April 1992 and his EMBA degree in finance and investment from Cheung Kong Graduate School of Business in April 2012.

As at the date of this announcement, Mr. Liu is not interested or deemed to be interested in shares, underlying shares or debentures of the Company or its associated corporation pursuant to Part XV of the Securities and Futures Ordinance (the “SFO”).

As at the date of this announcement, and save as disclosed above, Mr. Liu has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and is not related to any Director, senior management, other substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

Mr. Liu will enter into a letter of appointment with the Company and will hold office until the next general meeting of the Company following his appointment and be entitled for re-election at annual general meetings in accordance with the articles of association of the Company. Mr. Liu is entitled to a director's fee of RMB200,000 per annum, which is determined with reference to the fees paid by comparable companies, time, commitment, responsibilities of Mr. Liu and the Company's performance.

There is no information which is discloseable nor is Mr. Liu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Mr. Liu that need to be brought to the attention of the shareholders of the Company.

Mr. Liu has confirmed (i) his independence as regards each of the factors for independence referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that he does not have any past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence at the time of his appointment.

The Company has established the nomination committee to review and optimize the composition of the Board and to make recommendations to the Board regarding the appointment plans for directors. The Company has also adopted a board diversity policy, recognizing and embracing the benefits of having a diverse Board, and sees increasing diversity at the Board level as an essential element in supporting the attainment of the Company's strategic objectives and sustainable development.

The Board believes that Mr. Liu possesses the character, qualifications and integrity required to serve as directors of the Company. His professional qualifications, skills, knowledge and experience relevant to the Company's corporate strategy will further enhance the diversity of the Board, which will help the Board to consider issues from different perspectives, so as to make decisions in the best interests of the Company and its shareholders after appropriate review and assessment.

The Board believes that the joining of Mr. Liu will further enrich the Board's mix of knowledge, skills and experience, including but not limited to the fields of supply chain logistics, manufacturing, industrial automation and risk management, as well as provide cross-industry and cross-regional experience to the Company. With the joining of Mr. Liu, the Company will have four independent non-executive directors, each with diverse industry backgrounds, including law and corporate governance, accounting and finance, medical industry, business operations and risk management.

The nomination committee will continue to review the composition of the Board from time to time, and discuss the Board structure to ensure that it has a balance of expertise, skills and experience appropriate for the requirements of the business of the Company.

The Board hereby expresses its warmest welcome to Mr. Liu for his new appointment.

APPOINTMENT OF MEMBERS OF THE STRATEGIC COMMITTEE AND COMMERCIALIZATION COMMITTEE

The Board hereby announces that, following the establishment of the Strategic Committee and Commercialization Committee, the composition of each such committee is as set out below with effect from December 29, 2025:

The Strategic Committee consists of four members, including Dr. Zhang Jie, Mr. Xie Zhiyong, Mr. Li Zhiyong and Mr. Liu Thomas A., and Dr. Zhang Jie acts as the chairman.

The Commercialization Committee consists of five members, including Mr. Xie Zhiyong, Mr. Wang Yiqun Bruce, Mr. Liu Xudong, Mr. Li Zhiyong and Mr. Liu Thomas A., and Mr. Wang Yiqun Bruce acts as the chairman.

CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

The Board hereby announces the following changes to the composition of the audit committee of the Company (the "**Audit Committee**") and the remuneration committee of the Company (the "**Remuneration Committee**"), with effect from December 29, 2025:

Dr. Zhang Jie, a non-executive Director and the chairman of the Board, has been appointed as a member of the Remuneration Committee.

Mr. Xie Zhiyong, an executive Director, ceased to be a member of the Remuneration Committee.

Mr. Liu Thomas A., an independent non-executive Director, has been appointed as a member of the Audit Committee.

Mr. Li Zhiyong, an independent non-executive Director, ceased to be a member of the Audit Committee.

By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, December 29, 2025

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.